Publications by Professor Alan Boddy - ePrints

Browsing publications by Professor Alan Boddy.

Newcastle Authors	Title	Year
Professor Gareth Veal Julieann Sludden Dr David Jamieson Julie Errington Dr Ghada Malik et al.	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma	2016
Chris Walsh Dr Jennifer Bonner Professor Alan Boddy Professor Gareth Veal	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer	2016
Dr Nicola Cresti Dr Despina Televantou Dr David Jamieson Dr Mark Verrill Professor Alan Boddy et al.	Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance	2016
Barry Dent Laura Ogle Dr Rachel O'Donnell Dr Ujjal Mallick Professor Nicola Curtin et al.	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers	2016
Dr Yvette Drew Dr Martin Highley Julieann Sludden Dr James Murray Dr David Jamieson et al.	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer	2016
Professor Andrew Pearson Dr Quentin Campbell Hewson Professor Alan Boddy Melanie Griffin	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study	2015
Professor Alan Boddy	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer	2015
Dr James Murray Julieann Sludden Professor Alan Boddy Professor Nicola Curtin	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System	2015
Professor Alan Boddy	Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study	2014
Dr Anthony Oxley Philip Berry Gordon Taylor Dr Joe Cowell Dr Michael Hall et al.	An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion and vitamin A status in humans	2014
Dr Chris Hill Julie Errington Dr Ghada Malik Professor Alan Boddy Professor Gareth Veal et al.	Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer	2014
Barry Dent Dr Rachel O'Donnell Laura Ogle Padmini Ramesh Nick Hayes et al.	Detection and characterization of circulating tumor cells by imaging flow cytometry	2014
Dr David Jamieson Dr Jo Lee Dr Nicola Cresti Melanie Griffin Julieann Sludden et al.	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil	2014
Dr Hyun Jin Park Professor Georg Lietz Dr Anthony Oxley Professor Alan Boddy Philip Berry et al.	Simplified approaches for estimating vitamin A stores and β-carotene bioconversion in humans	2014
Professor Alan Boddy	Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samples	2014
Professor Gareth Veal Julie Errington Sophie Rowbotham Nicola Illingworth Dr Ghada Malik et al.	Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma	2013
Christopher Hill Dr David Jamieson Huw Thomas Dr Colin Brown Professor Alan Boddy et al.	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo	2013
Dr Anthony Oxley Philip Berry Professor John Hesketh Professor Alan Boddy Professor Georg Lietz et al.	Gender differences in retinol metabolism are independent of β-carotene bioconversion	2013
Professor Alan Boddy	Genetics of Cisplatin Ototoxicity: Confirming the Unexplained?	2013
Professor Gareth Veal Julie Errington Dr Ghada Malik Dr Chris Hill Professor Alan Boddy et al.	Investigating the pharmacokinetics and dosing of anticancer drugs in infants and young children	2013
Professor Alan Boddy	Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years	2013
Professor Alan Boddy Dr Alison Steel	The European Paediatric Oncology off-patent medicines Consortium (EPOC) pharmacokinetic/pharmacodynamic study of doxorubicin	2013
Professor Gareth Veal Professor Alan Boddy	Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring	2012
Professor Gareth Veal Professor Alan Boddy	Chemotherapy in newborns and preterm babies	2012
Professor Alan Boddy	Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring: Focus on IV Drug Administration	2012
Dr Emma Meczes Huw Thomas Professor Richard Edmondson Professor Gareth Veal Professor Alan Boddy et al.	Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours	2012
Professor Ruth Plummer Professor Alan Boddy Julieann Sludden	A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours	2011
Professor Alan Boddy Professor Ann Daly Professor Gareth Veal	Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases	2011
Professor Alan Boddy	Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example	2011
Dr David Jamieson Professor Alan Boddy	Pharmacogenetics of genes across the doxorubicin pathway	2011
Julie Errington Professor Alan Boddy Professor Gareth Veal Mike Cole	Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy	2011
Julie Errington Professor Alan Boddy Professor Gareth Veal Mike Cole	Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients	2011
Sue Green Professor Alan Boddy Dr Steven Cruickshank	The Birmingham Boron Neutron Capture Therapy (BNCT) Project: Developments towards Selective Internal Particle Therapy [abstract]	2011
Dr Simon Pridgeon Professor Rakesh Heer Gordon Taylor Professor Herbie Newell Kieran O'Toole et al.	Thiothymidine combined with UVA as a potential novel therapy for bladder cancer	2011
Dr David Jamieson Dr Nicola Cresti Julieann Sludden Melanie Griffin Nahed Hawsawi et al.	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy	2011
Melanie Griffin Professor Alan Boddy Professor Andrew Pearson	Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia	2010
Professor Alan Boddy	Boron neutron capture therapy (BNCT): Clinical optimization of uptake parameters of boronphenyllalanine (BPA)	2010
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Julieann Sludden Melanie Griffin Mike Cole Dr Mark Verrill Dr David Jamieson et al.	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide	2010
Mike Cole Professor Alan Boddy Professor Gareth Veal	Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate	2010
Professor Gareth Veal Julie Errington Professor Andrew Pearson Professor Alan Boddy	Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients	2010
Sophie Rowbotham Professor Alan Boddy Dr Chris Redfern Professor Gareth Veal Professor Ann Daly et al.	Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation	2010
Sophie Rowbotham Professor Ann Daly Professor Gareth Veal Professor Alan Boddy	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans	2010
Dr Agata Rozanska Dr Evan Mulligan Huw Thomas Deborah Castelbuono Professor Deborah Tweddle et al.	[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699	2009
Professor Alan Boddy	A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT	2009
Dr David Jamieson Dr Nicola Cresti Dr Mark Verrill Professor Alan Boddy	Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Professor Ruth Plummer Melanie Griffin Dr Sally Coulthard Julieann Sludden Professor Alan Calvert et al.	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors	2009
Julie Errington Professor Alan Boddy Professor Gareth Veal	Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma	2009
Professor Ruth Plummer Professor Alan Boddy Melanie Griffin Dr Mark Verrill	A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies	2008
Mike Cole Professor Alan Boddy Dr Michael Keir Professor Gareth Veal	Estimation of renal function and its potential impact on carboplatin dosing in children with cancer	2008
Professor Ruth Plummer Dr Christopher Jones Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors	2008
Professor Gareth Veal Professor Alan Boddy	Population pharmacokinetic investigation of actinomycin D in children and young adults	2008
Dr Patricia Turner Mike Cole Michael Batey Sandra Beare Professor Alan Boddy et al.	Reduced folate carrier single nucleotide polymorphism associated with methotrexate clearance in breast cancer patients	2008
Mike Cole Annie Parry Dr Michael Reid Professor Alan Boddy Professor Gareth Veal et al.	A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer	2007
Professor Gareth Veal Julie Errington Dr Michael Tilby Professor Alan Boddy	Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours	2007
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed	2007
Professor Alan Boddy Melanie Griffin Julie Errington Professor Gareth Veal	Dosing of cancer patients with low or absent renal function	2007
Dr Michael Keir Mike Cole Annie Parry Professor Alan Boddy Professor Gareth Veal et al.	Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing	2007
Dr Jane Renwick Gordon Taylor Huw Thomas Professor Alan Boddy Dr Chris Redfern et al.	Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo	2007
Dr David Jamieson Kerrie Wilson Dr Simon Pridgeon Dr Jane Margetts Professor Richard Edmondson et al.	NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism	2007
Professor Alan Boddy	Paclitaxel poliglumex. Antimitotic drug, Oncolytic.	2007
Professor Alan Boddy	Paclitaxel poliglumex: Antimitotic drug oncolytic	2007
Dr Jo Lee Dr Mark Verrill Julieann Sludden Melanie Griffin Sharon Erb et al.	Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer	2007
Professor Gareth Veal Mike Cole Geoffrey Taylor Julie Errington Professor Alan Boddy et al.	Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients	2007
Professor Alan Boddy Julieann Sludden Melanie Griffin Professor Herbie Newell Professor Stephen O'Brien et al.	Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia	2007
Professor Gareth Veal Mike Cole Julie Errington Professor Alan Boddy	Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group	2007
Professor Gareth Veal Sophie Rowbotham Professor Alan Boddy	Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma	2007
Professor Alan Calvert Professor Alan Boddy	Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group	2007
Professor Steven Clifford Rachel Daniel Dr Agata Rozanska Huw Thomas Professor Alan Boddy et al.	Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma	2007
Professor Gareth Veal Julie Errington Huw Thomas Professor Alan Boddy	Biliary excretion of etoposide in children with cancer	2006
Dr Jo Lee Julieann Sludden Professor Alan Boddy Dr Mark Verrill	Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.	2006
Mike Cole Professor Alan Boddy Dr Pamela Kearns Lisa Price Annie Parry et al.	Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?	2006
Professor Alan Boddy	Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy	2006
Dr David Jamieson Professor Alan Boddy	Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor	2006
Mark Leslie Julieann Sludden Professor Ruth Plummer Professor Alastair Greystoke Professor Alan Calvert et al.	A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.	2005
Professor Alan Boddy Professor Ruth Plummer Julieann Sludden Melanie Griffin Dr Mark Verrill et al.	A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules	2005
Professor Ruth Plummer Professor Alan Boddy Professor Nicola Curtin Professor Herbie Newell Lynsey Robson et al.	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide	2005
Dr Jane Renwick Professor Alan Boddy Dr Chris Redfern Professor Andrew Pearson Professor Gareth Veal et al.	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells	2005
Annie Parry Dr Michael Tilby Professor Dianne Ford Emerita Professor Suzanne Cholerton Professor Andrew Pearson et al.	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer	2005
Professor Gareth Veal Mike Cole Julie Errington Annie Parry Dr Juliet Hale et al.	Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study	2005
Dr Ashraf Azzabi Dr Andrew Hughes Dr Paula Calvert Professor Ruth Plummer Melanie Griffin et al.	Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations	2005
Professor Ruth Plummer Dr Christopher Jones Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1	2005
Professor Andrew Pearson Professor Alan Boddy	Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma	2004
Mike Cole Annie Parry Dr Michael Keir Professor Andrew Pearson Professor Alan Boddy et al.	Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹CR-EDTA population pharmacokinetics	2004
Professor Gareth Veal Professor Alan Boddy	Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy	2004
Professor Alan Boddy Gordon Taylor Dr Andrew Hughes Professor Alan Calvert Professor Herbie Newell et al.	2-[¹¹C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337	2003
Professor Gareth Veal Dr Sally Coulthard Professor Alan Boddy	Chemotherapy individualization	2003
Professor Gareth Veal Julie Errington Julieann Sludden Melanie Griffin Annie Parry et al.	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Julie Errington Professor Gareth Veal Julieann Sludden Melanie Griffin Professor Andrew Pearson et al.	Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Justin Armstrong Professor Gareth Veal Dr Chris Redfern Professor Alan Boddy	Effects of ketoconazole and acitretin on retinoid isomerisation and metabolism in neuroblastoma	2003
Dr Mark Verrill Professor Alan Boddy Julieann Sludden Kevin Fishwick Lynsey Robson et al.	Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors	2003
Professor Gareth Veal Julie Errington Professor Andrew Pearson Professor Alan Boddy	Poster Presentation: Oxidative metabolism of 13-cis-retinoic acid in children with neuroblastoma	2003
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	Potentiation of raltitrexed (RTX) in vitro by thymidine phosphorylase (TP) and TP distribution in vivo	2003
Professor Gareth Veal Julie Errington Dr Chris Redfern Professor Andrew Pearson Professor Alan Boddy et al.	Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells	2002
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Kevin Fishwick Lynsey Robson et al.	Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study	2002
Dr Andrew Hughes Dr Paula Calvert Dr Ashraf Azzabi Professor Ruth Plummer Melanie Griffin et al.	Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Huw Thomas Mike Cole Suzanne Elliott Professor Herbie Newell Professor Alan Calvert et al.	Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide	2002
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	The in vivo distribution of a CEA directed antibody conjugated to thymidine phosphorylase	2002
Dr Andrew Simpson Dr Paula Calvert Julieann Sludden Professor Alan Boddy Melanie Griffin et al.	Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules	2002
Professor Gareth Veal Melanie Griffin Annie Parry Dr Juliet Hale Professor Andrew Pearson et al.	A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin	2001
Professor Herbie Newell Professor Alan Boddy Geoffrey Taylor Andrew Johnston Professor Andrew Pearson et al.	A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation	2001
Professor Alan Boddy	All half-lives are wrong, but some half-lives are useful	2001
Dr Ian Sharkey Professor Alan Boddy	Body surface area estimation in children using weight alone: Application in paediatric oncology	2001
Professor Alan Boddy	Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children	2001
Mike Cole Professor Andrew Pearson Professor Alan Boddy	Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion	2001
Professor Alan Boddy Dr Martin Highley Dr John Fenwick Professor Alan Calvert	Estimation of glomerular filtration rate in cancer patients	2001
Professor Gareth Veal Dr Cinera Dias Annie Parry Julie Errington Dr Juliet Hale et al.	Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy	2001
Professor Gareth Veal Julie Errington Dr Chris Redfern Professor Andrew Pearson Professor Alan Boddy et al.	Influence of retinoid isomerisation on the cellular activity of 13-cis retinoic acid in neuroblastoma	2001
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer	2001
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Melanie Griffin Kevin Fishwick et al.	Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate	2001
Dr Xiaohong Lu Julie Errington Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines	2000
Dr Andrew Hughes Melanie Griffin Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel	2000
Melanie Griffin Professor Alan Boddy	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients	2000
Melanie Griffin Professor Alan Boddy	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients	2000
Professor Gareth Veal Dr Cinera Dias Professor Alan Boddy Annie Parry Dr Juliet Hale et al.	In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children	2000
Professor Alan Boddy	Metabolism and pharmacokinetics of oxazaphosphorines	2000
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer	2000
Huw Thomas Professor Alan Calvert Professor Alan Boddy	Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours	2000
Huw Thomas Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial	2000
Professor Alan Boddy Gordon Taylor	A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq® (nolatrexed dihydrochloride) given by 10-day oral administration	1999
Professor Alan Calvert Dr Martin Highley Professor John Lunec Professor Alan Boddy	Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene	1999
Mike Cole Professor Andrew Pearson Professor Alan Boddy	Cyclophosphamide metabolism in children with Fanconi's anaemia	1999
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Professor Herbie Newell Professor Alan Boddy et al.	Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days	1999
Michael Batey Kevin Fishwick Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert et al.	Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer	1999
Professor Gareth Veal Professor Alan Boddy Huw Thomas Annie Parry Professor Andrew Pearson et al.	Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy	1999
Professor Alan Boddy	Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients	1999
Mike Cole Emerita Professor Suzanne Cholerton Professor Ann Daly Professor Andrew Pearson Professor Alan Boddy et al.	The effect of fluconazole on cyclophosphamide metabolism in children	1999
Mike Cole Professor Andrew Pearson Professor Alan Boddy	Cyclophosphamide metabolism in children with Fanconi's anaemia	1998
Gordon Taylor Professor Herbie Newell Professor Alan Boddy Andrew Johnston Professor Andrew Pearson et al.	Deoxyuridine plasma levels during the phase I study of nolatrexed in children with advanced cancer	1998
Professor Alan Boddy Huw Thomas	High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours	1998
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ ^TM) and paclitaxel in patients with advanced solid tumours	1998
Professor Alan Boddy Melanie Griffin Dr Margaret Little Professor Andrew Pearson	Pharmacokinetics and blood distribution in paediatric patients of SPI-77: Cisplatin encapsulated in Stealth® liposomes	1998
Professor Alan Boddy	Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer	1998
Professor Alan Boddy Gordon Taylor Professor Herbie Newell Professor Alan Calvert	Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors	1998
Huw Thomas Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Validation of pharmacologically-guided dosing of carboplatin in paediatric patients	1998
Professor Alan Boddy Huw Thomas Lynsey Robson Professor Alan Calvert	A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer	1997
Professor Alan Boddy Professor Andrew Pearson Dr Michael Tilby Professor Herbie Newell	Cisplatin pharmacokinetics in children with cancer	1997
Professor Andrew Pearson Professor Alan Boddy	Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children	1997
Professor Alan Boddy	Pharmacogenetics in cancer etiology and chemotherapy	1997
Dr Michael Tilby Professor Andrew Pearson Professor Alan Boddy Professor Herbie Newell	Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy	1997
Professor Alan Boddy Huw Thomas	RMP-7. Potential as an adjuvant to the drug treatment of brain tumours	1997
Professor Steve Wedge Fiona Chapman Gordon Taylor Huw Thomas Professor Alan Boddy et al.	A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid	1996
Professor Alan Boddy Mike Cole Professor Andrew Pearson	Cyclophosphamide pharmacokinetics in children	1996
Professor Alan Boddy Huw Thomas Professor Herbie Newell Professor Alan Calvert Lynsey Robson et al.	Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study	1996
Professor Alan Boddy Professor Andrew Pearson Professor Roderick Skinner	Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics	1996
Professor Alan Boddy Professor Andrew Pearson	Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration	1996
Professor Alan Boddy Professor Andrew Pearson	Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration	1996
Professor Alan Boddy Professor Herbie Newell Professor Andrew Pearson	Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis	1996
Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Population pharmacokinetics of carboplatin in children	1996
Professor Alan Boddy Professor Andrew Pearson	Comparison of continuous infusion and bolus administration of ifosfamide in children	1995
Professor Alan Boddy Mike Cole Professor Andrew Pearson Professor Herbie Newell	Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients	1995
Professor Alan Boddy	Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients	1995
Professor Alan Calvert Professor Alan Boddy Dr Andrew Hughes Lynsey Robson Huw Thomas et al.	Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.	1995
Gordon Taylor Professor Alan Boddy Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion	1995
Professor Steve Wedge Gordon Taylor Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement	1995
Professor Alan Boddy Mike Cole Professor Andrew Pearson	Cyclophosphamide Metabolism in Children	1995
Professor Alan Boddy Mike Cole Professor Andrew Pearson	The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion	1995
Professor Alan Boddy Emerita Professor Suzanne Cholerton Professor Ann Daly Professor Andrew Pearson	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide	1994
Professor Alan Boddy Professor Andrew Pearson Dr Michael Tilby Professor Herbie Newell	The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review.	1994
Dr Hilary Wynne Professor Alan Boddy	The Association of Age and Frailty with the Pharmacokinetics and Pharmacodynamics of Metoclopramide	1993
Professor Alan Boddy Professor Andrew Pearson	Pharmacokinetics and Metabolism of Ifosfamide Administered as a Continuous Infusion in Children	1993
Professor Andrew Pearson Professor Alan Boddy	Reproducibility of Methods Relating to Cyclophosphamide Metabolic Studies; response	1993
Professor Alan Boddy	The role of pharmacogenetics in chemotherapy: modulation of tumor response and host toxicity	1993
Professor Alan Boddy	Combined thin-layer chromatography—photography—densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma	1992
Professor Alan Boddy	Comparative anticonvulsant potency and pharmacokinetics of (+)- and (−)-enantiomers of stiripentol	1992
Professor Alan Boddy	Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide	1992
Professor Alan Boddy Professor Andrew Pearson	Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients	1992
Professor Alan Boddy Emerita Professor Suzanne Cholerton Professor Ann Daly Professor Janice Ellis Julian Leathart et al.	The pharmacogenetics of chemical carcinogenesis	1992
Professor Alan Boddy	Application of a linear recirculation model to drug targeting	1991
Professor Alan Boddy	Introduction: Abstracts of poster presentations: Polymorphic Urinary Metabolite Profile of Cyclophosphamide in Turkish Patients	1991